Table 2.
Endocrine treatment
| Parameter | Category | Palbociclib N = 300 n (valid %) |
Placebo N = 316 n (valid %) |
Overall N = 616 n (valid %) |
P value |
|---|---|---|---|---|---|
| Start of ET | Before palbociclib/placebo | 272 (90.7) | 286 (90.5) | 558 (90.6) | 1.000 |
| Concomitantly with palbociclib/placebo | 28 (9.3) | 30 (9.5) | 58 (9.4) | ||
| First ET | Tamoxifen alone | 199 (66.3) | 208 (66.8) | 407 (66.1) | 0.932 |
| Tamoxifen plus OFS | 61 (20.3) | 58 (18.4) | 119 (19.3) | 0.542 | |
| AI plus OFS | 37 (12.3) | 47 (14.9) | 84 (13.6) | 0.411 | |
| Letrozole plus OFS | 18 (6.0) | 20 (6.3) | 38 (6.2) | ||
| Exemestane plus OFS | 15 (5.0) | 20 (6.3) | 35 (5.7) | ||
| Anastrozole plus OFS | 4 (1.3) | 7 (2.2) | 11 (1.8) | ||
| AI alonea | 3 | 3 | 6 | 1.000 | |
| OFS | 98 (32.7) | 105 (33.2) | 203 (33.0) | ||
| Type of OFS | Goserelin | 90 (30.0) | 94 (29.7) | 184 (29.9) | |
| Other GnRHa | 7 (2.3) | 11 (3.5) | 18 (2.9) | ||
| Surgical | 1 | 0 | 1 | ||
| Radiologic | 0 | 0 | 0 | ||
| Start of GnRHa during study therapy | 11 (3.7) | 17 (5.4) | 28 (4.5) | ||
Type of first ET in premenopausal patients.
AI, aromatase inhibitor; ET, endocrine therapy; GnRHa, gonadotropin-releasing hormone analogue; OFS, ovarian function suppression.
a
Patients receiving AI alone and were excluded from analyses according to ET treatment.